An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
HeartBeam to Present at Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) will present at the Dawson James Small Cap Growth Conference on October 12, 2022 in Jupiter, FL, and at The ThinkEquity Conference on October 26, 2022 in New York City. The company's leadership team, including CEO Branislav Vajdic, will conduct presentations and one-on-one meetings. HeartBeam has developed a unique 3D-vector ECG platform for heart attack detection, enhancing patient care through rapid assessment of heart symptoms.
Positive
None.
Negative
None.
SANTA CLARA, Calif.--(BUSINESS WIRE)--
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, will present at the Dawson James Small Cap Growth Conference being held at the Wyndham Grand Hotel in Jupiter, FL on October 12, 2022, and The ThinkEquity Conference taking place at the Mandarin Oriental Hotel in New York City on October 26, 2022.
HeartBeam Chief Executive Officer and Founder Branislav Vajdic, PhD, Chief Financial Officer Rick Brounstein, and Chief Business Officer Jon Hunt, PhD, will conduct in-person one-on-one meetings and deliver the Company’s presentations which can be viewed live and via replay at the webcast link below and will also be available on the HeartBeam investor relations website at ir.heartbeam.com.
Dawson James Small Cap Growth Conference Date: October 12, 2022 Location: Jupiter, FL Presentation Time: October 12, 2022, at 10:00 am ET (7:00 am PT) in TRACK 2 - Preserve Ballroom B
Webcast: https://wsw.com/webcast/dawson7/beatw/2191545
Format: In-person 1x1’s and Presentations
Speakers: Chief Executive Officer and Founder Branislav Vajdic, PhD, Chief Financial Officer Rick Brounstein, Chief Business Officer Jon Hunt, PhD
Conference Website: Click here
The ThinkEquity Conference Date: October 26, 2022 Location: New York City Presentation Time: October 26, 2022, at 4:30 pm ET (1:30 pm PT) in South Salon II
Webcast: https://wsw.com/webcast/tep23/beatw/1805130
Format: In-person 1x1’s and Presentations
Speakers: Chief Executive Officer and Founder Branislav Vajdic, PhD, Chief Financial Officer Rick Brounstein, Chief Business Officer Jon Hunt, PhD
Conference Website: Click here
For more information on the Dawson James Small Cap Growth or ThinkEquity Conferences, or to schedule a one-on-one meeting with HeartBeam management, please contact your conference representative or you may also email your request to BEAT@mzgroup.us or call Chris Tyson at (949) 491-8235.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI™ is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo™ is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies. For more information, visit HeartBeam.com.
